| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Biogen Inc (NASDAQ: BIIB)
BIIB Technical Analysis
5
| As on 9th Jun 2023 BIIB SHARE Price closed @ 308.88 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 224.00 & Strong Buy for SHORT-TERM with Stoploss of 224.14 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BIIBSHARE Price
| Open | 308.88 | Change | Price | % |
| High | 308.88 | 1 Day | 0.00 | 0.00 |
| Low | 308.88 | 1 Week | 12.47 | 4.21 |
| Close | 308.88 | 1 Month | 15.16 | 5.16 |
| Volume | 159 | 1 Year | 74.23 | 31.63 |
| 52 Week High 318.06 | 52 Week Low 187.54 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BIIB Daily Charts |
BIIB Intraday Charts |
Whats New @ Bazaartrend |
BIIB Free Analysis |
|
|
BIIB Important Levels Intraday
| RESISTANCE | 308.88 |
| RESISTANCE | 308.88 |
| RESISTANCE | 308.88 |
| RESISTANCE | 308.88 |
| RESISTANCE | 308.88 |
| RESISTANCE | 308.88 |
| RESISTANCE | 308.88 |
| RESISTANCE | 308.88 |
BIIB Forecast April 2024
| 4th UP Forecast | 375.63 |
| 3rd UP Forecast | 354.22 |
| 2nd UP Forecast | 340.99 |
| 1st UP Forecast | 327.76 |
| 1st DOWN Forecast | 290 |
| 2nd DOWN Forecast | 276.77 |
| 3rd DOWN Forecast | 263.54 |
| 4th DOWN Forecast | 242.13 |
BIIB Weekly Forecast
| 4th UP Forecast | 372.82 |
| 3rd UP Forecast | 352.31 |
| 2nd UP Forecast | 339.64 |
| 1st UP Forecast | 326.96 |
| 1st DOWN Forecast | 290.80 |
| 2nd DOWN Forecast | 278.12 |
| 3rd DOWN Forecast | 265.45 |
| 4th DOWN Forecast | 244.94 |
BIIB Forecast2024
| 4th UP Forecast | 564.36 |
| 3rd UP Forecast | 482.43 |
| 2nd UP Forecast | 431.78 |
| 1st UP Forecast | 381.14 |
| 1st DOWN Forecast | 236.62 |
| 2nd DOWN Forecast | 185.98 |
| 3rd DOWN Forecast | 135.33 |
| 4th DOWN Forecast | 53.4 |
Biogen Inc ( NASDAQ USA Symbol : BIIB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BIIB Business Profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Address: 225 Binney Street, Cambridge, MA, United States, 02142
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service